Technical Analysis for BCRX - BioCryst Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade C 4.97 1.84% 0.09
BCRX closed up 1.84 percent on Wednesday, December 13, 2017, on 1.24 times normal volume.
Track This Stock
Watchlist Portfolio
Trend Table & Recent Alerts
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Up Up
See historical BCRX trend table...

Date Alert Name Type % Chg
Dec 13 Calm After Storm Range Contraction 0.00%
Dec 13 Wide Bands Range Expansion 0.00%
Dec 12 Calm After Storm Range Contraction 1.84%
Dec 12 NR7 Range Contraction 1.84%
Dec 12 Wide Bands Range Expansion 1.84%
Dec 11 Wide Bands Range Expansion -1.00%
Dec 11 Upper Bollinger Band Touch Strength -1.00%
Dec 8 Crossed Above 50 DMA Bullish -4.61%
Dec 8 MACD Bullish Centerline Cross Bullish -4.61%
Dec 8 MACD Bullish Signal Line Cross Bullish -4.61%

Older signals for BCRX ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio.
Basic chart:

Profile
BioCryst Pharmaceuticals, Inc., a biotechnology company, designs, optimizes, and develops novel drugs that block key enzymes involved in the pathogenesis of diseases. The company integrates the disciplines of biology, crystallography, medicinal chemistry, and computer modeling to discover and develop small molecule pharmaceuticals through the structure-guided drug design process. Its product candidates include peramivir, an intravenous neuraminidase inhibitor, which is approved for seasonal influenza in Japan and Korea, as well as in Phase III clinical trials for acute influenza; ulodesine, an oral purine nucleoside phosphorylase inhibitor, which has completed Phase II clinical trials for the treatment of gout; and forodesine, an oral purine nucleoside phosphorylase inhibitor that is in Phase II clinical trials for oncology. The company's product candidates also comprise BCX4161, a Phase I oral serine protease inhibitor for kallikrein hereditary angioedema; and BCX4430, a preclinical, RNA dependent-RNA polymerase inhibitor for treating Filoviruses. It has collaborative relationships with Mundipharma International Holdings Limited for the development and commercialization of forodesine; and Shionogi & Co., Ltd. and Green Cross Corporation for the development and commercialization of peramivir. Biocryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
Is BCRX a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 1 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 9.25
52 Week Low 3.95
Average Volume 1,006,203
200-Day Moving Average 5.7106
50-Day Moving Average 4.785
20-Day Moving Average 4.7425
10-Day Moving Average 4.867
Average True Range 0.2782
ADX 15.71
+DI 24.87
-DI 12.82
Chandelier Exit (Long, 3 ATRs ) 4.4554
Chandelier Exit (Short, 3 ATRs ) 5.2646
Upper Bollinger Band 5.1401
Lower Bollinger Band 4.3449
Percent B (%b) 0.79
BandWidth 16.767528
MACD Line 0.0538
MACD Signal Line 0.0195
MACD Histogram 0.0344
Fundamentals Value
Market Cap 399.73 Million
Num Shares 80.4 Million
EPS -0.62
Price-to-Earnings (P/E) Ratio -8.02
Price-to-Sales 11.43
Price-to-Book 13.91
PEG Ratio -0.28
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 5.37
Resistance 3 (R3) 5.38 5.25 5.30
Resistance 2 (R2) 5.25 5.15 5.25 5.28
Resistance 1 (R1) 5.11 5.09 5.18 5.10 5.26
Pivot Point 4.99 4.99 5.02 4.98 4.99
Support 1 (S1) 4.85 4.88 4.92 4.84 4.68
Support 2 (S2) 4.72 4.82 4.72 4.66
Support 3 (S3) 4.58 4.72 4.64
Support 4 (S4) 4.57